These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

222 related items for PubMed ID: 8704208

  • 1. Antisense oligodeoxynucleotide combination therapy of primary chronic myelogenous leukemia blast crisis in SCID mice.
    Skorski T, Nieborowska-Skorska M, Wlodarski P, Zon G, Iozzo RV, Calabretta B.
    Blood; 1996 Aug 01; 88(3):1005-12. PubMed ID: 8704208
    [Abstract] [Full Text] [Related]

  • 2. Treatment of Philadelphia leukemia in severe combined immunodeficient mice by combination of cyclophosphamide and bcr/abl antisense oligodeoxynucleotides.
    Skorski T, Nieborowska-Skorska M, Wlodarski P, Perrotti D, Hoser G, Kawiak J, Majewski M, Christensen L, Iozzo RV, Calabretta B.
    J Natl Cancer Inst; 1997 Jan 15; 89(2):124-33. PubMed ID: 8998181
    [Abstract] [Full Text] [Related]

  • 3. Potential therapeutic applications of antisense oligodeoxynucleotides in the treatment of chronic myelogenous leukemia.
    Gewirtz AM.
    Leuk Lymphoma; 1993 Jan 15; 11 Suppl 1():131-7. PubMed ID: 7504543
    [Abstract] [Full Text] [Related]

  • 4. Effects of BCR-ABL antisense oligonucleotides (AS-ODN) on human chronic myeloid leukemic cells: AS-ODN as effective purging agents.
    Wu AG, Joshi SS, Chan WC, Iversen PL, Jackson JD, Kessinger A, Pirruccello SJ, Sanger WG, Sharp JG, Verbik DJ.
    Leuk Lymphoma; 1995 Dec 15; 20(1-2):67-76. PubMed ID: 8750625
    [Abstract] [Full Text] [Related]

  • 5. Leukemia treatment in severe combined immunodeficiency mice by antisense oligodeoxynucleotides targeting cooperating oncogenes.
    Skorski T, Nieborowska-Skorska M, Campbell K, Iozzo RV, Zon G, Darzynkiewicz Z, Calabretta B.
    J Exp Med; 1995 Dec 01; 182(6):1645-53. PubMed ID: 7500009
    [Abstract] [Full Text] [Related]

  • 6. Effect of bcr-abl oligodeoxynucleotides on the clonogenic growth of chronic myelogenous leukaemia cells.
    de Fabritiis P, Skorski T, De Propris MS, Paggi MG, Nieborowska-Skorska M, Lisci A, Buffolino S, Campbell K, Geiser T, Calabretta B.
    Leukemia; 1997 Jun 01; 11(6):811-9. PubMed ID: 9177433
    [Abstract] [Full Text] [Related]

  • 7. Interferon-alpha and bcr-abl antisense oligodeoxynucleotides in combination enhance the antileukemic effect and the adherence of CML progenitors to preformed stroma.
    Bellucci R, Sala R, De Propris MS, Cordone I, de Fabritiis P.
    Leuk Lymphoma; 1999 Nov 01; 35(5-6):471-81. PubMed ID: 10609784
    [Abstract] [Full Text] [Related]

  • 8. Suppression of Philadelphia1 leukemia cell growth in mice by BCR-ABL antisense oligodeoxynucleotide.
    Skorski T, Nieborowska-Skorska M, Nicolaides NC, Szczylik C, Iversen P, Iozzo RV, Zon G, Calabretta B.
    Proc Natl Acad Sci U S A; 1994 May 10; 91(10):4504-8. PubMed ID: 8183938
    [Abstract] [Full Text] [Related]

  • 9. Antisense oligodeoxynucleotides for the treatment of chronic myelogenous leukemia: are they still a promise?
    de Fabritiis P, Calabretta B.
    Haematologica; 1995 May 10; 80(4):295-9. PubMed ID: 7590496
    [No Abstract] [Full Text] [Related]

  • 10. Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells.
    Skorski T, Kanakaraj P, Nieborowska-Skorska M, Ratajczak MZ, Wen SC, Zon G, Gewirtz AM, Perussia B, Calabretta B.
    Blood; 1995 Jul 15; 86(2):726-36. PubMed ID: 7606002
    [Abstract] [Full Text] [Related]

  • 11. Selective inhibition of leukemia cell proliferation by BCR-ABL antisense oligodeoxynucleotides.
    Szczylik C, Skorski T, Nicolaides NC, Manzella L, Malaguarnera L, Venturelli D, Gewirtz AM, Calabretta B.
    Science; 1991 Aug 02; 253(5019):562-5. PubMed ID: 1857987
    [Abstract] [Full Text] [Related]

  • 12. Gene-targeted specific inhibition of chronic myeloid leukemia cell growth by BCR-ABL antisense oligodeoxynucleotides.
    Skórski T, Szczylik C, Malaguarnera L, Calabretta B.
    Folia Histochem Cytobiol; 1991 Aug 02; 29(3):85-9. PubMed ID: 1794439
    [Abstract] [Full Text] [Related]

  • 13. Antitumor effect of c-myc antisense phosphorothioate oligodeoxynucleotides on human melanoma cells in vitro and and in mice.
    Leonetti C, D'Agnano I, Lozupone F, Valentini A, Geiser T, Zon G, Calabretta B, Citro G C, Zupi G.
    J Natl Cancer Inst; 1996 Apr 03; 88(7):419-29. PubMed ID: 8618233
    [Abstract] [Full Text] [Related]

  • 14. IL-2 inhibits proliferation of K562 cells and reduces accumulation of bcr/abl mRNA and oncoprotein.
    Dilloo D, Hanenberg H, Lion T, Burdach S.
    Leukemia; 1995 Mar 03; 9(3):419-24. PubMed ID: 7885040
    [Abstract] [Full Text] [Related]

  • 15. Specific antisense oligomer anti Bcr-abl junctions in chronic myeloid leukemia: a cell cycle analysis and CFU-GM study.
    Mahon FX, Belloc F, Vianes I, Barbot C, Boiron JM, Cowen D, Lacombe F, Brizard A, Bilhou-Nabera C, Bernard P.
    Leuk Lymphoma; 1995 Nov 03; 19(5-6):423-9. PubMed ID: 8590842
    [Abstract] [Full Text] [Related]

  • 16. The influence of phosphorothioate oligodeoxynucleotides on various organs in vivo.
    Nieborowska-Skórska M, Białek AP, Nicolaides NC, Iozzo RV, Kawalec M, Calabretta B, Kawiak J, Marlicz K, Skórski T.
    Folia Histochem Cytobiol; 1996 Nov 03; 34(2):69-73. PubMed ID: 8875213
    [Abstract] [Full Text] [Related]

  • 17. BCR-ABL antisense oligodeoxynucleotide in vitro purging and autologous bone marrow transplantation for patients with chronic myelogenous leukemia in advanced phase.
    de Fabritiis P, Petti MC, Montefusco E, De Propris MS, Sala R, Bellucci R, Mancini M, Lisci A, Bonetto F, Geiser T, Calabretta B, Mandelli F.
    Blood; 1998 May 01; 91(9):3156-62. PubMed ID: 9558370
    [Abstract] [Full Text] [Related]

  • 18. Acute- and chronic-phase chronic myelogenous leukemia colony-forming units are highly sensitive to the growth inhibitory effects of c-myb antisense oligodeoxynucleotides.
    Ratajczak MZ, Hijiya N, Catani L, DeRiel K, Luger SM, McGlave P, Gewirtz AM.
    Blood; 1992 Apr 15; 79(8):1956-61. PubMed ID: 1562723
    [Abstract] [Full Text] [Related]

  • 19. BCR-ABL antisense oligodeoxyribonucleotides suppress the growth of leukemic and normal hematopoietic cells by a sequence-specific but nonantisense mechanism.
    Vaerman JL, Lammineur C, Moureau P, Lewalle P, Deldime F, Blumenfeld M, Martiat P.
    Blood; 1995 Nov 15; 86(10):3891-6. PubMed ID: 7579358
    [Abstract] [Full Text] [Related]

  • 20. Bcr-Abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: a novel model for chronic myelogenous leukemia.
    Zhang X, Ren R.
    Blood; 1998 Nov 15; 92(10):3829-40. PubMed ID: 9808576
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.